Phase I, Open-Label, Randomized, 3-Way Crossover Study to Assess Relative Bioavailability of Single Oral Dose of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E in Healthy Volunteers.

Trial Profile

Phase I, Open-Label, Randomized, 3-Way Crossover Study to Assess Relative Bioavailability of Single Oral Dose of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2010

At a glance

  • Drugs Esomeprazole/naproxen; Naproxen
  • Indications Arthritis; Musculoskeletal pain; NSAID-induced gastrointestinal damage
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 Mar 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 18 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top